An early exploratory study of GC012F injection in the treatment of CD19 and/or BCMA positive relapsed or refractory B-cell non-Hodgkin's lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 0120 (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man

04 Jun 2024 Results (As of data cut-off on January 30th, 2024) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
15 Jun 2023 Updated Results(n=9 at data cut-off of January 16th, 2023) assessing safety and efficacy of of Cd19/Bcma Dual-Targeting Fast Car-T Gc012f for patients with relapsed/refractory B-Cell non-Hodgkins Lymphoma presented at the 28th Congress of the European Haematology Association
10 Jun 2023 According to a Gracell Biotechnology media release, data from this study were presented at the European Hematology Association (EHA2023) Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com